Literature DB >> 9883616

[The adverse reactions of anti-tuberculosis drugs and its management].

M Wada1.   

Abstract

This paper reviews adverse reactions to anti-tuberculous drugs. Hepatotoxicity occur with isoniazid, rifampicin, pyrazinamide and ethionamide. Risk factors include high age, malnutrition and high alcohol consumption. Liver function should be followed every two weeks to prevent serious hepatotoxicity. If this occurs drugs should be stopped until improvement of liver functions. Fulminant hepatitis has poorer prognosis in regimen with pyrazinamide than without. The Combination of pyrazinamide and ethionamide is frequently hepatotoxic and should be avoided. Gastric reactions occur frequently. Elderly persons are highly intolerant to rifampicin. Peripheral neuritis is reported with isoniazid, ethambutol and ethionamide, but effectively prevented with pyridoxine. Allergic reaction including fever or rash occur with many anti-tuberculosis drugs. If necessary desensitization to re-introduce the drugs. Ocular toxicity due to ethambutol occur infrequently with a dose of 15 mg/kg. Drug interactions are frequent in tuberculosis treatment. Rifampicin reduce serum the concentration of such drugs as Methadone, Corticosteroid, and Theophylline.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883616

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  8 in total

1.  Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Authors:  Nacer Lounis; Nicolas Veziris; Aurélie Chauffour; Chantal Truffot-Pernot; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

2.  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Authors:  Nicolas Veziris; Chantal Truffot-Pernot; Alexandra Aubry; Vincent Jarlier; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

3.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

4.  Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs.

Authors:  Meghna-R Adhvaryu; Narsimha Reddy; Minoo H Parabia
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

5.  Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.

Authors:  Meghna R Adhvaryu; Narsimha Reddy; Bhasker C Vakharia
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

6.  Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis.

Authors:  Jaya Faujdar; Pushpa Gupta; Mohan Natrajan; Ram Das; D S Chauhan; V M Katoch; U D Gupta
Journal:  Indian J Med Res       Date:  2011-11       Impact factor: 2.375

7.  National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program.

Authors:  Driss Soussi Tanani; Samira Serragui; Sanae Hammi; Latifa Ait Moussa; Abdelmajid Soulaymani; Rachida Soulaymani; Yahia Cherrah
Journal:  Pan Afr Med J       Date:  2017-01-31

8.  Pharmacovigilance and moroccan tuberculosis public program: current situation.

Authors:  Driss Soussi Tanani; Amina Tebaa; Raja Benkirane; Kenza Bennani; Ghali Iraqi; Abdelmajid Soulaymani; Rachida Soulaymani Bencheikh
Journal:  Tuberc Res Treat       Date:  2014-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.